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Background. Methamphetamine (MAP) users present to the emergency department (ED) for myriad reasons, including trauma,
chest pain, and psychosis. The purpose of this study is to determine how their prevalence, demographics, and resource utilization
have changed.Methods. Retrospective review of MAP patients over 3 months in 2016. Demographics, mode of arrival, presenting
complaints, disposition, and concomitant cocaine/ethanol use were compared to a 1996 study at the same ED. Results. 638 MAP-
positive patients, 3,013 toxicology screens, and 20,203 ED visits represented an increase in prevalence compared to 1996: 461 MAP-
positive patients, 3,102 screens, and 32,156 visits.MAPpatients were older compared to the past.Mode of arrival wasmost frequently
by ambulance but at a lower proportion than 1996, as was the proportion of MAP patients with positive cocaine toxicology screens
and ethanol coingestion. Admission rate was lower compared to the past, as was discharge to jail. The proportion of MAP patients
presenting with blunt trauma was lower compared to the past and higher for chest pain. Conclusion. A significant increase in
the prevalence of MAP-positive patients was found. Differences in presenting complaints and resource utilization may reflect the
shifting demographics of MAP users, as highlighted by an older patient population relative to the past.
1. Introduction
At present, amphetamines may be legally prescribed for
treatment of narcolepsy and attention deficit hyperactiv-
ity disorders. Amphetamine and its derivatives, such as
methamphetamine (MAP), were first synthesized in the early
20th century and marketed as bronchodilators [1]. However,
after their introduction, these drugs were soon used for
myriad unrelated conditions, such as for weight loss and
to increase wakefulness. Legal availability of amphetamines
led to widespread use until being designated as controlled
Schedule II drugs in 1970. After this, MAP faded from
popularity until the late 1980s, where it reappeared in the
western United States and Hawaii [2]. In 1989, Derlet and
coworkers published the first study of patients with MAP
toxicity in the emergency department (ED) and found that
agitation, hallucinations, suicidal behavior, and chest pain
were the most common presenting complaints [3]. During
the 1990s, MAP use continued to grow in the Northwest
and Southwest. By the millennium, MAP use had become
entrenched in the Midwest as well and to a lesser degree in
the South, Northeast, and Mid-Atlantic states [4]. During
this period, authors of the National Survey on Drug Use
and Health (NSDUH) estimated that MAP use increased
from approximately 2% of the adult population in 1994 to
5% over the following decade [5]. Patients abusing MAP
present to the ED for acute cardiovascular, psychiatric,
toxicologic, neurologic, and traumatic disorders [6]. Richards
and associates published the first study of ED utilization by
MAP users versus nonusers in 1996 and found significantly
higher rates of arrival by ambulance and admission to the
hospital [7].TheUnited States Drug AbuseWarningNetwork
(DAWN) began monitoring MAP-associated ED visits in
1995 and reported 11,002 visits in 1996 [8]. From the last
published DAWN report in 2014, there were 102,961 MAP-
associated ED visits in 2011 [9].
Methamphetamine use continues to be a significant
problemdomestically andworldwide. From themost recently
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published NSDUH in 2015, approximately 897,000 people
aged 12 or older were current users of MAP, a substantial
increase from 569,000 in the prior year [10]. From a global
perspective, there are over 24 million estimated regular MAP
users [10]. The United States has consistently reported the
largest amount of MAP seizures by law enforcement each
year, followed by East and Southeast Asia, where these have
quadrupled between 2009 and 2014 [11–13]. Eastern Europe,
Russia, Oceania, and the Middle East have also experienced
a growing number of MAP users during recent years [12,
14–16]. As the prevalence of MAP use continues to rise
throughout the country, we repeated the original 1996 study
of ED utilization 20 years later to determine if this was an
institutional trend as well and to further characterize this
patient subgroup.
2. Methods
This study was performed over a three-month period from
May to August 2016 at the University of California, Davis
Medical Center, an urban, academic Level I trauma center
with an annual ED census of 80,000 visits. This ED serves a
population of 500,000 within the Sacramento city limits and
1.6million in the surrounding area.The hospital also serves as
a tertiary referral center for Northern and Central California
and is the de facto public hospital, providing care for a signif-
icant number of uninsured and/or dispossessed patients, as
well as those brought in by law enforcement from the street,
jails, prisons, and detention centers. A retrospective review
of patients presenting to the ED with MAP-positive urine
toxicology screens was undertaken. Collected data included
demographics, mode of arrival, presenting complaints, dis-
position, and ethanol level, which was then compared to a
similar study performed at the same ED 20 years previously.
The electronic medical record of each patient was accessed,
and data were recorded on a standardized form by the study
authors. Interrater reliability was not evaluated. The qualita-
tive urine toxicology screen was performed using a UniCel
DxC 800 Synchron (Beckman Coulter Inc., Brea, California)
to detect MAP and other drugs of abuse. There is no stan-
dardized protocol in place at our ED for ordering toxicology
screens, with the exception of trauma patients admitted
to the hospital and patients on 72-hour psychiatric holds.
Otherwise, the decision to obtain toxicology screens is at the
discretion of the treating clinician. Data were entered into
Excel (version 14, Microsoft, Redmond, Washington) and
analyzed with Stata (version 12, StataCorp, College Station,
Texas). Statistical analysis was performed using chi-square
and unpaired Student’s t-tests. Results are reported as mean
± standard deviation (SD) unless otherwise stated. Statistical
significance is assumed at a level of 𝑃 ≤ 0.05. This study was
approved by the institutional review board at our institution.
3. Results
For the three-month period in 2016, a total of 638 patients
were identified as MAP-positive out of 3,013 total urine
toxicology screens and 20,203 ED patient visits. In the 1996
study over a six-month period, there were 461 MAP-positive
patients from a total of 3,102 toxicology screens and 32,156
ED visits This represented a significant increase in both
the prevalence of MAP-positive toxicology screens in 2016
compared to 1996 (21.2% versus 14.9%) and the proportion
of MAP-positive patients presenting to the ED (3.2% versus
1.4%). Differences in demographics, ED arrival, disposition,
and concomitant ethanol and cocaine use are shown in
Table 1. Methamphetamine patients were significantly older
compared to the past (41.6 ± 12.6 versus 34.9 ± 8.5 years), but
there was no gender difference observed. The most frequent
mode of arrival was by ambulance but at a lower proportion
compared to the past (52% versus 69.2%). Racial comparison
revealed no significant differences, with the majority of users
identified as Caucasian.
With regard tomedical insurance status, a higher propor-
tion of MAP-positive patients in 2016 had state, federal, or
commercially funded medical insurance compared to 1996.
A lower proportion of MAP-positive patients in 2016 had
positive cocaine toxicology screens than in 1996 (4.4% versus
7.4%) as well as ethanol coingestion (12.4% versus 20%).
Admission rate in 2016 was significantly lower compared to
the past (41.2% versus 58.1%) as was discharge directly to jail
(1.3% versus 8.9%). Presenting complaints between the time
periods are compared in Table 2. The proportion of MAP-
positive patients presenting with blunt trauma was signifi-
cantly lower than the past (12.2% versus 33%, 𝑃 = 0.0001)
and higher for chest pain (16% versus 7.8%, 𝑃 = 0.0001).
4. Discussion
At present, this study is the first inwhichMAPprevalence and
user characteristics have been compared at the same medical
treatment facility over a two-decade period of time. Our
finding of increasingMAP prevalence parallels findings from
multiple national and worldwide databases. Attempts to hin-
der domestic MAP production by outlawing specific chem-
ical precursors such as phenylacetone, pseudoephedrine,
and ephedrine has resulted in a decrease in domestic MAP
production by 56 percent from 2010 to 2015 [17]. However,
the United States Drug Enforcement Agency (DEA) reports
that Mexico has now become the major supplier of MAP
[17, 18]. According to the 2016 National Drug Threat Survey,
almost one-third of responding law enforcement agencies
reported MAP as the greatest drug threat in their areas,
specifically in the Southwest,West Central,West Coastal, and
Southeast regions, and it is the drug that most contributes
to violent crime [17]. Decreasing drug price and increasing
purity may be contributing factors to the recent increase in
MAP prevalence: DEA analysis of domestic MAP purchases
from 2007 through 2015 revealed that the price per gram of
pure MAP decreased by 57% from $152 to $66, while the
purity increased from 56% to 92% [17].
There seems to be no indication that the trend of
increasing MAP prevalence will reverse in the near future.
Data from Quest Diagnostics (Madison, New Jersey), which
performs screening tests for drugs of abuse for employers
and hospitals, indicates a steady rise in the prevalence of
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Table 1: Demographics, mode of arrival, disposition, and coingestions of MAP-positive patients, 2016 versus 1996.
2016 1996 % change 95% CI 𝑃
𝑛 (%) 𝑛 (%)
Prevalence 638/20,203 (3.2) 461/32,156 (1.4) 1.8 1.5–2.1 <0.0001
Positive MAP screen 638/3013 (21.2) 461/3102 (14.9) 6.3 4.4–8.2 <0.0001
Age ± SD 41.6 ± 12.6 34.9 ± 8.5 <0.0001†
Gender 0.97
Male 409 (64.1) 295 (64.0) 0.1 −5.7–5.9
Female 229 (35.9) 166 (36.0) −0.1 −5.7–5.9
Race 0.4
Caucasian 451 (70.7) 341 (74.0) −3.3 −2.2–8.7 0.23
Hispanic 107 (16.8) 63 (13.6) 3.2 −1.2–7.5 0.15
African American 46 (7.2) 37 (8.0) −0.8 −2.5–4.2 0.62
Asian/Pacific Islander 33 (5.2) 18 (3.9) 1.3 −1.4–3.9 0.31
Native American 1 (0.1) 2 (0.5) −0.4 −0.4–1.6 0.21
Insurance <0.00001
None/Self-pay 172 (27.0) 385 (83.5) −56.5 51.3–61.2 <0.0001
MediCal/MediCare 396 (62.0) 56 (12.2) 49.6 44.7–54.5 <0.0001
HMO/MCO 70 (11.0) 20 (4.3) 6.7 3.4–9.8 0.0001
Mode of arrival <0.00001
Ambulance 332 (52.0) 319 (69.2) −17.2 11.3–22.9 <0.0001
Ambulatory 156 (24.4) 66 (14.3) 10.1 5.3–14.8 <0.0001
Police 121 (19.0) 56 (12.1) 6.9 2.4–11.2 0.002
Transfer 29 (4.6) 20 (4.4) 0.2 2.5–2.8 0.87
Coingestion
Ethanol 79 (12.4) 92 (20) −7.6 3.1–12.2 0.0006
Ethanol level (mg/dL) 148 ± 116.2 125 ± 32 0.07†
Cocaine 28 (4.4) 34 (7) −2.6 −0.3–5.7 0.06
Disposition <0.00001
Admit 263 (41.2) 268 (58.1) −16.9 10.8–22.9 <0.0001
Discharge∗ 144 (22.5) 89 (19.3) 3.2 −1.8–8.1 0.2
Psychiatric hold/transfer 223 (35.0) 63 (13.7) 21.3 16.2–26.2 <0.0001
Jail 8 (1.3) 41 (8.9) −7.6 4.9–10.7 <0.0001
∗ includes patients who eloped; †Student’s 푡-test. MAP: methamphetamine; HMO/MCO: health maintenance organization/managed care organization; CI:
confidence interval.
Table 2: Presenting complaints of MAP-positive patients, 2016 versus 1996.
2016 1996 % change 95% CI 𝑃
𝑛 (%) 𝑛 (%)
Blunt trauma 78 (12.2) 152 (33.0) −20.8 15.7–25.9 <0.0001
Altered LOC 185 (29.0) 108 (23.4) 5.6 0.2–10.9 0.04
Abdomen pain 54 (8.5) 58 (12.6) −4.1 0.3–8.0 0.03
Suicide attempt/ideation 67 (10.5) 38 (8.2) 2.3 1.4–5.8 0.2
Chest pain 102 (16.0) 36 (7.8) 8.2 4.2–12.0 0.0001
Skin infection 45 (7.0) 28 (6.1) 0.9 −2.3–3.9 0.55
Penetrating trauma 30 (4.7) 20 (4.4) 0.3 −2.4–2.9 0.81
Miscarriage 7 (1.1) 8 (1.7) −0.6 −0.9–2.4 0.4
Ingestion 47 (7.4) 8 (1.7) 5.7 3.2–8.2 <0.0001
Headache 23 (3.6) 5 (1.1) 2.5 0.6–4.4 0.009
Total 638 461 <0.0001
MAP: methamphetamine; LOC: level of consciousness; CI: confidence interval.
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positive tests for MAP over the past 5 years [19]. Information
from the Treatment Episode Data Set (TEDS) from 2003 to
2013 indicates a rise in the number of people admitted for
MAP treatment in both the state of California and nationwide
[20, 21]. In San Diego, California, MAP prevalence in adult
arrestees increased from 28% in 2000 to 41% in 2013 formales
and from 29% to 46% in females [22]. In Sacramento County,
where our study was conducted, MAP was detected in 27%
of patients admitted to the county-funded Mental Health
Treatment Center’s Intake Stabilization Unit in 2015, and ED
visits for MAP-related complaints increased 85% versus 13%
for all patients over a 3-year period [23]. An analysis ofMAP-
screening test positivity by zip code showed Sacramento
County to have a rate of 1.7%–3.8%, which represented the
highest tier recorded statewide, along with Los Angeles and
San Diego [19].
There have been a small number of studies focusing on
MAP use and ED care at our institution [3, 24–31]. The first
appeared in 1989, when Derlet and colleagues published a
retrospective study ofMAP patients presenting to our ED [3].
Over a 6-month period in 1987, 127MAP-positive patients out
of a total of 18,510 were identified. This represents prevalence
of 0.7% compared to our findings of 1.4% in 1996 and 3.2%
in 2016. Gender proportion (65% male) was similar to 1996
and 2016, and 54% were aged 30 years and older. Admission
rate was 19%, compared to 58.1% in 1996 and 41.2% in 2016.
Psychiatric hold and admission rate was 49% versus 13.7% in
1996 and 35% in 2016. Patients presenting with trauma were
not included in their study, but two-thirds were brought to
the ED for alteredmental status or being found unresponsive.
In the next few studies, Richards and associates examined
the treatment of MAP-induced agitation and investigated
the association of rhabdomyolysis, tooth wear, and acute
coronary syndrome (ACS) with MAP use [24, 26–28].
Schermer and Wisner investigated the association of
MAP with trauma from 1989 to 1994 at our institution and
reported that MAP prevalence in 18,004 trauma patients
increased from7.4% to 13.4% compared to cocaine rates (5.8%
to 6.2%) and ethanol (43% to 35%) [25]. Similar to our find-
ings, MAP-positive patients were most likely to be male and
Caucasian and to be involved in motor vehicle and motor-
cycle collisions. This was in contradistinction to cocaine-
positive patients, who were most commonly non-Caucasian
and were injured by assaults, gunshot, or stab wounds. In
another trauma-based study of 10,663 subjects at our hospital
from 2002 to 2006, London et al. determined that minimally
injured (Injury Severity Score < 9) MAP-positive patients
incurred more cost and utilized more hospital resources than
non-MAP patients [29]. Demographics and racial profile
were similar to our study and the aforementioned trauma
study years earlier, and mechanism of injury was predomi-
nantly blunt trauma. Insurance status was assessed, and 49%
ofMAP-positive patients were uninsured, which fell between
our findings of 83.5% in 1996 and 27% in 2016. Potential rea-
sons for the increased costs and hospital resource utilization
were from the acute effects of MAP, resulting in an unreliable
physical examination, tachycardia, and acidosis, suggesting
shock fromoccult injury, and alteredmental status raising the
possibility of head injury. Patients with MAP toxicity may be
hypersomnolent duringmetabolismof the drug and repletion
of monoamines and adenosine triphosphate (ATP), delaying
discharge while increasing length of stay [30].
Lee et al. then performed a study from 2004 to 2006 in
which 318 MAP patients’ self-reporting of their drug use was
correlated to their toxicology screen [31]. The authors deter-
mined that the self-report rate for MAP-positive patients was
52%, highlighting the importance of toxicology screening in
the diagnostic process. A final study was performed between
2009 and 2010 to determine the prevalence of MAP in
1,207 psychiatric patients evaluated in our ED and whether
detection of MAP on toxicology screening was associated
with involuntary 72-hour holds [32]. The authors reported
MAP prevalence of 15%, which was closer to our 1996
findings and lower than 2016. Demographics were similar to
our findings, although 41% of MAP-positive patients were
uninsured compared to 27% of MAP-negative patients. This
rate fell between our findings in 1996 and 2016.
There have been a small number of studies performed
at other hospitals which have focused on the utilization of
resources by MAP-positive patients. Tominaga et al. studied
212 Hawaiian trauma patients in 2002 and reported MAP
prevalence of 27% [33]. Patients who were MAP-positive
were most likely to have injuries frommotor vehicle collision
or blunt force assault rather than from penetrating trauma.
Similar to previous studies from our institution, they also
had higher length of stay, intensive care unit admissions,
and hospital charges [25, 29]. In 2005, Gray and coworkers
examined 13,125 patients visits at a major Australian ED
and determined MAP prevalence rate of 1.2%, similar to
our finding in 1996 [34]. It is important to note that there
was no toxicology screening for MAP in their study; rather
patient history and judgment of the treating clinician were
used instead, and this likely underestimatedMAPprevalence.
Admission and arrival by ambulance rates were 40% and
32%, respectively, which were lower than our study. Another
Australian study of the same period reported similar results
[35]. Hendrickson et al. conducted an observational study in
2006 of MAP-related ED visits in an urban, academic Level
I trauma center similar to ours and reported a prevalence
rate of 2.4%, which fell between our 1996 and 2016 rates [36].
The authors reported similar demographics, an uninsured
rate of 50%, and predominance of psychiatric and trauma-
related diagnoses. Methamphetamine-related chest pain was
reported at a much lower rate (3.1%) than our 1996 (7.8%)
and 2016 (16%) rates.This same research group also published
a study of MAP-related psychiatric visits at their ED during
the same time period [37]. High ED utilization rates were
reported in a 2005 to 2007 study of 427 at-risk youths who
injected MAP in Vancouver, Canada [38]. A comparative
study performed 10 years apart (2004 and 2013) of mental
health presentations to EDs in Victoria, Australia, found that
the number of patients with concurrent MAP exposure more
than doubled from 2.2 to 4.3% [39].
The number of MAP-related ED visits over the past
decade has been analyzed using data fromDAWN and nearly
doubled from 67,954 in 2007 to 102,961 in 2011 [40]. Gender
trends were largely unchanged, reflecting male predomi-
nance, and there was an increase inMAPpatients aged 55 and
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higher. Admission rate to the hospital during this period was
36%, similar to our 2016 findings. This trend towards older
age of MAP use may reflect changing national demographics
as a result of declining fertility and rising longevity, referred
to as the “Silver Tsunami” [41–43]. Older MAP users may
have more experience with drug dosing and frequency of use
and may be cannier than younger users [41, 44]. Ageing may
also be a factor in the lower rate of blunt trauma from car
and motorcycle collisions seen from our analysis; the traffic
collision rate has been shown to decline with age as older
drivers may be more skilled and have higher risk aversion
compared to younger drivers [45]. Chronic MAP use has
been associated with ACS and the development of cardiomy-
opathy, whichmay also be reflected by a trend towards higher
age and ED presentations of chest pain in our study, which
more than doubled in 2016 compared to 1996 [28, 46].
The racial distribution observed in our study did not
change significantly from 1996 compared to 2016, with
predominance of Caucasian MAP users. This trend was also
seen in all aforementioned studies and government agency
reports regarding demographics of MAP users. This racial
distribution does not reflect the most recent census taken for
our county, in which 45% of the population are identified
as Caucasian, 27% as Hispanic, 14.6% as African American,
and 18% as Asian [47]. Although MAP and cocaine are
stimulants, the two drugs do not appear to substitute for
the each other or share a common user group [25, 48]. One
explanation for this is geographic, in that cocaine use is more
common in inner cities, whereas MAP use is more common
in suburban or rural areas [49]. Insurance status significantly
changed in 2016, with only 27% uninsured compared to
84% in 1996. One likely explanation for this is the passage
of the Patient Protection and Affordable Care Act of 2010,
which resulted in a significant reduction in the number of the
uninsured in the United States [50, 51]. Another cause could
be increased use of MAP by more patients with employer-
based insurance, as the unemployment rate declined over
the past few years [52]. This would be consistent with the
trend of less coingestion of cocaine and ethanol found in our
2016 data. In theory, a working population may be interested
in increased wakefulness and stamina from MAP, enabling
longer work hours or several jobs, as opposed to the short-
term effect of cocaine or depressant effect of ethanol from
alcohol or cocaine.
There were significant differences between 2016 and 1996
with regard to mode of arrival, with decreasing ambulance
use and increasing ambulatory and police transport rate.
These trends may be linked to the increasing number of
MAP-positive patients who presented as walk-ins to the ED
for mental health issues such as suicidal ideation and/or
attempts, depression, anxiety, and acute psychosis. One rea-
son for this is that Sacramento County withdrew funding for
the majority of public mental health clinics and residential
treatment facilities several years ago, leaving these patients in
a void [53]. Our ED, as well as many others in the area, has
taken over this role which has led to serious overcrowding
and hallway boarding of ambulatory patients on 72-hour
psychiatric holds [53, 54]. Unfortunately, this is not a regional
phenomenon [55, 56]. Other factors affecting mode of arrival
include transport by police of MAP users with erratic behav-
ior or public intoxication, represented in Table 2 as altered
level of consciousness and ingestion. Police are often called
in first in lieu of an ambulance for these types of public
disturbances. In the past, these patients were often brought
directly to jail or publically funded detoxification centers.
Now they are most likely to be brought to the ED as a result
of California Proposition 47, which was passed in 2014 and
reducedmany nonviolent crimes tomisdemeanors, including
possession of MAP [57, 58]. The impact of Proposition 47
can also be seen with discharge directly to jail rates, which
significantly decreased compared to 1996 [59].
The decreased hospital admission rate of 2016 compared
to 1996 reflects a national trend. The American Hospital
Association reported a 7%decline in inpatient admissions per
capita between 2008 and 2012 [60]. This may be partly due to
the implementation of the two-midnight census rule by the
Centers for Medicare and Medicaid Services (CMS) in 2013
and increasing number of Accountable Care Organization
(ACO) hospital network affiliations. Increasing numbers of
insured patients have more access to outpatient treatment
options from the ED rather than inpatient admission. With
regard to the declining rate of blunt trauma observed in our
study, it is possible that this trend also reflects a state and
nationwide trend [61, 62]. The United States has experienced
a 31% reduction in its motor vehicle death rate per capita over
the past 13 years [61].There are fewer nonfatal injuries as well
when the year 2016 is compared to 1996 [63, 64].
5. Limitations
There are several limitations associated with this study. First,
it is a retrospective review performed over a span of a
few months. As such, it represents a “snapshot” in time
of the MAP problem in our ED patient population, and
the proportions recorded for the study could possibly have
changed over the course of months to years. A longitudinal
study would have been the best method to study the trend
of MAP use and ED utilization, but this was not possible
due to the scale of the project and unavailability of patient
data after electronic medical record implementation 10 years
after the first study was published. There is no standardized
protocol in place at our ED for ordering toxicology screens,
with the exception of trauma patients admitted to the hospital
and on 72-hour psychiatric holds. Otherwise, the decision to
obtain toxicology screens is at the discretion of the treating
clinician, which may have led to sampling bias. The area
served by our ED is noted to have higher than average levels of
MAP consumption and production, and toxicology screens
may not be ordered if patients give a history of MAP use.
As such, our results may actually have underestimated the
prevalence ofMAP in our patient population. As it is a single-
center study, results may not be applicable to other regional
medical centers. No quantitative confirmation of MAP-
positive screens was performed, and it is possible that false-
positive or false-negative screens may have been recorded.
Definitive association between MAP use and each patient’s
presenting complaint was not possible as the amount of time
6 Journal of Addiction
elapsed between last MAP dose and ED presentation could
not be established.The half-life of MAP is up to 12 hours, and
toxicology screens may remain positive for up to 72 hours.
Therefore, the results of this study only pertain to general
consumption of MAP by our ED patients who were tested.
6. Conclusions
Compared to 20 years earlier, a significant increase has
occurred in the prevalence ofMAP-positive patients present-
ing to our ED,which parallels statewide, domestic, andworld-
wide trends. Resource utilization has also changed, such as a
lower rate of arrival by ambulance and hospital admissions.
The lower proportion of blunt trauma and higher proportion
of chest pain may reflect the shifting demographics of MAP
users, as highlighted by an older patient population than in
the past. Emergency clinicians will continue to be on the
forefront of care for MAP patients presenting acutely to the
ED for amyriad of medical, traumatic, and psychiatric issues.
Toxicology screening of patients with suspected drug use
and unexplained symptoms may be clinically and financially
useful in this setting by decreasing laboratory and imaging
testing, admission to the hospital, and length of stay. Unless
there are major changes in focused law enforcement onMAP,
penalties for production and possession, international border
control, availability, pricing, and rehabilitation options for
treatment of MAP addiction, the problem is predicted to
continue its seemingly inexorable rise.
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